Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dys
2011-06-21 MedSci原创 MedSci原创
Czaja, A. J. (2011). "Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria." Gastroenterology 140(5): 1472-1480. BACKGROUND & AIMS: The diagnos
Czaja, A. J. (2011). "Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria." Gastroenterology 140(5): 1472-1480.
BACKGROUND & AIMS: The diagnostic scoring systems for autoimmune hepatitis categorize some patients as having probable disease; this designation can affect treatment strategies and recruitment to clinical studies. A retrospective study was performed to determine the bases for the classification of probable autoimmune hepatitis and its clinical importance. METHODS: The study included 185 adult patients who had been assessed at presentation for findings common to both international diagnostic scoring systems. RESULTS: Seventeen patients (9%) were graded as probable autoimmune hepatitis by the revised original scoring system, and 28 patients (15%) were similarly designated by the simplified scoring system. These patients were distinguished from those designated as definite autoimmune hepatitis by male sex, concurrent immune diseases, lower serum gamma-globulin and immunoglobulin G levels, and lower titers of autoantibody. Patients with definite or probable designations by either scoring system responded similarly to conventional corticosteroid regimens during comparable intervals of treatment. Full, partial, or nonresponses and treatment dependence were evident in all diagnostic categories with similar frequencies. Twenty-seven patients designated as probable autoimmune hepatitis by one system were designated as definite autoimmune hepatitis by the other system. CONCLUSIONS: The designation of probable autoimmune hepatitis by the international scoring systems is based on differences in clinical manifestations and does not reflect differences in the validity of the diagnosis or its treatment response. Large multicenter prospective studies are necessary to establish these observations.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#IOP#
33
#High#
26
#CIN#
19
#Bio#
0
#GAS#
28
#AST#
32
#ASIA#
28
#Dysplasia#
17
#gastric#
32
#carcinoma#
35